evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

42 questions · 48 findings · 8 reviews · Vascular

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 8 · 16.7%GRADE not reported 5 · 10.4%Very low 2 · 4.2%Low 19 · 39.6%Moderate 8 · 16.7%High 6 · 12.5%

Heparin vs placebo

Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Heparin showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).

1 finding from 1 review

Heparin vs placebo

Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Heparin showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).

1 finding from 1 review

Heparin vs placebo

Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Heparin showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs unfractionated heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with intravenous unfractionated heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent VTE at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Symptomatic recurrent DVT at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in symptomatic recurrent DVT at 3 months compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Unfractionated heparin vs low molecular weight heparin

DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity

It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Low molecular weight heparin vs active control

Symptomatic PE · ambulatory cancer patients receiving chemotherapy

Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.

3 findings from 1 review